首页> 外文OA文献 >PCN152 Cost-Minimization Analysis of Bevacizumab Verse Cetuximab in First-Line Treatment for Metastatic Colorectal Cancer in Kras Wild-Type Patients in the Supplementary Health Care System in Brazil

【2h】

PCN152 Cost-Minimization Analysis of Bevacizumab Verse Cetuximab in First-Line Treatment for Metastatic Colorectal Cancer in Kras Wild-Type Patients in the Supplementary Health Care System in Brazil

机译：巴西补充性医疗保健系统中的贝伐单抗和西妥昔单抗贝伐单抗/西妥昔单抗用于转移性结直肠癌一线治疗的Kras野生型患者的PCN152成本最小化分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Tsuchiya C.T.; Kim H.S.J.; Maximo M.F.M.; Ramos L.A.;
展开▼
作者单位

展开▼
年度 2014
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. COST-MINIMIZATION ANALYSIS OF BEVACIZUMAB COMPARED TO CETUXIMAB AND PANITUMUMAB IN FIRST-LINE TREATMENT OF KRAS WILD-TYPE METASTATIC COLORECTAL CANCER IN FRANCE [J] . Gherardi A., Masia C., Plommet N. Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research . 2016,第7期

机译：在法国一线治疗KRAS野生型转移性大肠癌中，与西妥昔单抗和帕尼妥珠单抗相比，贝伐单抗的成本最小化分析
2. COST-MINIMIZATION ANALYSIS OF PANITUMUMAB COMPARED WITH CETUXIMAB IN THE FIRST-LINE TREATMENT OF WILD-TYPE RAS METASTATIC COLORECTAL CANCER PATIENTS IN BRAZIL [J] . dos Santos R. F., Riveros B. S., Nita M. E., Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research . 2016,第7期

机译：帕妥替尼单抗与西妥昔单抗相比在巴西一线治疗野生型转移性结肠直肠癌患者的成本最小化分析
3. CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial)(aEuro) [J] . Michl M., Stintzing S., Fischer von Weikersthal L., Annals of oncology: official journal of the European Society for Medical Oncology . 2016,第8期

机译：在接受一线FOLFIRI加西妥昔单抗或贝伐单抗治疗的KRAS外显子2野生型和扩展RAS野生型转移性结直肠癌患者中，CEA反应与肿瘤反应和生存相关（FIRE-3试验）（aEuro）
4. Isolation of Circulating Tumor Cells from Patients with Metastatic Colorectal Cancer Using Label-Free Microfluidic Technology for Enumeration and Detection of KRAS, BRAF, PIK3CA Mutation [C] . Haiyan Emily Liu, Evelyn Kidess-Sigal, Melanie Triboulet, International Molecular Medicine Tri-Conference. . 2016

机译：使用无标记微流体技术分离转移性结肠直肠癌患者的循环肿瘤细胞进行募准和检测KRA，BRAF，PIK3CA突变
5. Comparative Analysis on Innate Immune System Function in Metastatic Breast, Colorectal, and Prostate Cancer Patients with Circulating Tumor Cells [D] . Santos, Mark Anthony Francisco. 2014

机译：转移性乳腺癌，结直肠癌和前列腺癌患者循环肿瘤细胞先天免疫系统功能的比较分析
6. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer [O] . Alan P. Venook, Donna Niedzwiecki, Heinz-Josef Lenz, -1

机译：一线化疗联合西妥昔单抗或贝伐单抗对KRAS野生型晚期或转移性结直肠癌患者总体生存的影响
7. Cost-Minimization Analysis of Bevacizumab Compared to Cetuximab and Panitumumab in First-Line Treatment of Kras Wild-Type Metastatic Colorectal Cancer in France [O] . A Gherardi, C Masia, N Plommet 2016

机译：贝伐单抗与西妥昔单抗与潘培姆中的成本最小化分析与法国克拉野生型转移性结直肠癌的一线治疗

PCN152 Cost-Minimization Analysis of Bevacizumab Verse Cetuximab in First-Line Treatment for Metastatic Colorectal Cancer in Kras Wild-Type Patients in the Supplementary Health Care System in Brazil

著录项

引文网络

相似文献

相关主题

期刊订阅